Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Radiation therapy just got a serious speed upgrade. Penn Medicine has launched the first U.S. Phase I clinical trial of ConformalFLASH® proton therapy — a technique that delivers cancer-killing radiation in under a second. The trial targets patients with recurrent, inoperable head and neck cancer, offering just five treatments over 10 days instead of the usual five to six weeks of daily sessions.
Penn Medicine's Abramson Cancer Center has launched the first U.S. Phase I clinical trial of ConformalFLASH® proton therapy — a cutting-edge technique that delivers a full dose of cancer-killing radiation in less than a second. Unlike conventional radiation, which spreads treatment across 25–35 daily sessions over five to six weeks, this approach condenses everything into just five sessions over roughly 10 days.
The trial will enroll 10 patients with recurrent, inoperable head and neck cancer — a group with limited options and notoriously difficult side effect profiles from repeat radiation. What makes this trial unique is its use of conformal 3D targeting, meaning the radiation beam is precisely mapped to the tumor's boundaries to minimize damage to surrounding healthy tissue. Previous FLASH trials used a simpler "shoot-through" method without this precision.
By the Numbers:
Why it matters: If FLASH proton therapy proves safe and feasible, it could dramatically reduce treatment burden for cancer patients — less time in hospitals, fewer side effects, and a better quality of life. Success here would pave the way for larger trials across other cancer types.
